Actively Recruiting
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
Led by The First Affiliated Hospital of Xiamen University · Updated on 2025-02-19
33
Participants Needed
1
Research Sites
214 weeks
Total Duration
On this page
Sponsors
T
The First Affiliated Hospital of Xiamen University
Lead Sponsor
F
Fujian Provincial Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
To observe the safety and efficacy of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.
CONDITIONS
Official Title
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with follicular lymphoma grade 1-3a and received at least second-line treatment including anti-CD20 monoclonal antibody
- Age 18 years or older
- Estimated survival time over 3 months
- ECOG performance status 2 or less
- Able to follow study requirements
- At least one measurable lesion larger than 1.5 cm in lymph nodes or larger than 1 cm in extranodal sites confirmed by CT or MRI
- Able to understand and voluntarily provide informed consent
You will not qualify if you...
- Central nervous system involvement currently or previously
- Evidence of transformation to a more aggressive lymphoma subtype
- Impaired bone marrow function or liver function beyond specific limits
- Severe kidney dysfunction with eGFR less than 30 ml/min
- Abnormal blood clotting tests or enzyme levels above defined thresholds
- Active infections including HIV, hepatitis B or C, or CMV infection with positive tests
- Significant heart rhythm disorders or severe cardiovascular diseases
- History of stroke or brain bleeding within 6 months
- Major surgery within 4 weeks before enrollment
- Prior use of PI3K inhibitors with disease progression during treatment within 6 months
- Systemic anti-tumor therapy or radiotherapy within 4 weeks before enrollment
- Participation in other drug clinical trials within 2 weeks or use of small molecule drugs within 4 weeks before enrollment
- Hematopoietic stem cell transplantation within specified recent periods or active graft-versus-host disease
- Use of strong CYP3A4 enzyme inducers or inhibitors within 2 weeks before first drug administration
- Toxicity from previous anti-tumor therapy not resolved to grade 1 or less except hair loss
- Uncontrolled systemic infection requiring intravenous antibiotics
- Presence of other primary tumors requiring active treatment
- Inability to take oral drugs due to surgery or serious gastrointestinal disease
- Pregnant or lactating women
- Any other significant medical condition or abnormal test that may affect safety or study results as judged by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Bing Xu
Xiamen, Fujian, China, 361000
Actively Recruiting
Research Team
B
Bing Xu
CONTACT
Z
Zhifeng Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here